Cyclosporin A Clinical Trials

Size	Price	Qty
50mg	USD 147
200mg	USD 297

Clinical Trials

Numerous clinical trials spanning Phase 1 through Phase 4 and unassigned studies evaluate Cyclosporin A across diverse indications, including renal transplantation complications, hypertrophic cardiomyopathy, acute myeloid leukemia, vernal keratoconjunctivitis, and post-transplant glycemic control. Supported by academic institutions, university hospitals, and government entities, these investigations reflect varied recruitment statuses ranging from not yet recruiting and actively recruiting to completed and unknown.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06903884	RECRUITING	Vernal Keratoconjunctivitis	The University of Hong Kong	2026-02-09	PHASE3
NCT04239859	NOT_YET_RECRUITING	Plaque Psoriasis	Singapore General Hospital	2024-01	PHASE4
NCT04547049	ACTIVE_NOT_RECRUITING	Leukemia; MDS	First Affiliated Hospital of Zhejiang University	2020-09-01	PHASE3
NCT06802055	RECRUITING	Aplastic Anaemia	Peking Union Medical College Hospital	2025-01-25	PHASE2
NCT04945096	UNKNOWN	Engraft Failure; Relapse; GVHD	The First Affiliated Hospital of Soochow University	2021-07-01	PHASE3
NCT06525948	UNKNOWN	Aplastic Anemia; Transfusion-dependent Anemia	Peking Union Medical College Hospital	2024-07-30	PHASE4
NCT06246786	WITHDRAWN	Triple Negative Breast Cancer; DNA Damage Repair Deficiency	Virginia G. Kaklamani	2024-07-01	EARLY_PHASE1
NCT06944132	COMPLETED	Pterygium; Pterygium of the Conjunctiva and Cornea	Benha University	2024-04-01
NCT06366685	Not yet recruiting	Esophageal Cancer\|Exercise Training\|Psychotherapy\|Rehabilitation	Mengmeng Yuan\|Anhui Medical University	2024-05-01	Not Applicable
NCT06320561	Not yet recruiting	Stroke	Vrije Universiteit Brussel\|University Ghent\|Research Foundation Flanders	2024-05	--
NCT05702931	Not yet recruiting	Hyperglycemia\|Renal Transplant Complication Primary Non-Function\|Diabetes	Rigshospitalet Denmark\|Aarhus University Hospital\|Odense University Hospital	2024-04-01	Phase 4
NCT06052761	Recruiting	Child in Hospital	Adiyaman University	2024-02-10	Not Applicable
NCT05692843	UNKNOWN	Atopic Dermatitis	Instituto de Investigación Hospital Universitario La Paz	2022-10-10	PHASE4
NCT05771012	COMPLETED	Management of Punctal Stenosis	Farwaniya Hospital	2021-01-01
NCT03026946	UNKNOWN	Hand Eczema	University Medical Center Groningen	2017-05-29	PHASE3
NCT04376528	UNKNOWN	Hepatitis, Autoimmune; Primary Biliary Cholangitis; Immunosuppression	West China Hospital	2021-06-16	PHASE4
NCT02370550	UNKNOWN	Sjogren's Syndrome	Peking University People's Hospital	2015-03	PHASE4
NCT03896971	COMPLETED	Aplastic Anemia	Safaa AA Khaled	2019-11-15	PHASE4
NCT04540926	UNKNOWN	COVID 19 Pneumonia	Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado	2020-09	PHASE1; PHASE2
NCT04451239	UNKNOWN	Keratonjunctivitis	Ameera Gamal Abdelhameed	2020-06-30
NCT02487069	COMPLETED	Acute Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome	Nanfang Hospital, Southern Medical University	2015-06
NCT02472054	COMPLETED	Hemophagocytic Lymphohistiocytosis (HLH)	Assistance Publique - Hôpitaux de Paris	2015-06-29	PHASE1; PHASE2
NCT02876250	WITHDRAWN	Lung Transplantation	Hospices Civils de Lyon	2017-01	PHASE3
NCT02834468	UNKNOWN	Immune Thrombocytopenia	Shandong University	2016-06	PHASE3
NCT02706470	UNKNOWN	Miscarriage, Recurrent	Fudan University	2016-05	PHASE2; PHASE3
NCT01760096	UNKNOWN	Paroxysmal Nocturnal Hemoglobinuria; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Proteinuria; Urination Disorders; Thrombosis; Bone Marrow Failure; Aplastic Anemia,; Anemia, Hemolytic	Institute of Hematology & Blood Diseases Hospital, China	2013-01	PHASE2
NCT01642979	UNKNOWN	Paroxysmal Nocturnal Hemoglobinuria; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Proteinuria; Urination Disorders; Thrombosis; Bone Marrow Failure; Aplastic Anemia,; Anemia, Hemolytic	Institute of Hematology & Blood Diseases Hospital, China	2012-07	PHASE2
NCT01843348	COMPLETED	Kidney Transplantation; Renal Transplantation	Novartis Pharmaceuticals	2012-12-27	PHASE3
NCT01766375	UNKNOWN	Acute Myeloid Leukemia	Guangxi Medical University	2012-08	PHASE3
NCT02199964	TERMINATED	Dry Eye	Baylor College of Medicine	2014-03
NCT02203422	WITHDRAWN	Immune Thrombocytopenia	Shandong University	2014-07	PHASE3
NCT02314312	UNKNOWN	Transplantation of Kidney; Expanded Criteria Donor; ECD	Mahidol University	2012-01	PHASE3
NCT00167583	COMPLETED	Behcet's Disease; Panuveitis; Posterior Uveitis; Retinal Vasculitis	University Hospital Tuebingen	2004-11	PHASE3
NCT01693393	COMPLETED	Sjögren´s Syndrome	Charite University, Berlin, Germany	2010-03	PHASE2
NCT01182662	UNKNOWN	Aplastic Anemia	Shandong University	2010-08	PHASE2
NCT00332839	TERMINATED	Renal Transplantation	Novartis Pharmaceuticals	2005-11	PHASE4
NCT00956293	TERMINATED	Renal Transplantation	Novartis Pharmaceuticals	2009-07	PHASE4
NCT00513474	COMPLETED	Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms	Massachusetts General Hospital	2008-01	PHASE1
NCT00176865	COMPLETED	Hemophagocytic Lymphohistiocytosis; X-Linked Lymphoproliferative Disorders; Chediak-Higashi Syndrome; Griscelli Syndrome; Immunologic Deficiency Syndromes; Langerhans-Cell Histiocytosis	Masonic Cancer Center, University of Minnesota	2002-08	PHASE2
NCT00303667	COMPLETED	Acute Myelogenous Leukemia	Masonic Cancer Center, University of Minnesota	2005-01	PHASE1; PHASE2
NCT01527240	COMPLETED	Stroke	Hospices Civils de Lyon	2009-10	PHASE2
NCT00520468	COMPLETED	Myelodysplastic Syndrome	M.D. Anderson Cancer Center	2004-06	PHASE2
NCT00565669	COMPLETED	Dry Eye Syndrome	Medical University of South Carolina	2007-10
NCT00375895	TERMINATED	Chronic Hepatitis C; Evidence of Liver Transplantation	Rennes University Hospital	2006-06	PHASE3
NCT00359814	COMPLETED	Heart Transplantation	Hannover Medical School	2004-11
NCT00359658	COMPLETED	Heart Transplantation	Hannover Medical School	2004-11
NCT01163942	TERMINATED	Aplastic Anaemia	European Society for Blood and Marrow Transplantation	2001-03	PHASE3
NCT00114777	COMPLETED	Renal Transplantation	Bristol-Myers Squibb	2005-02	PHASE3
NCT00521924	TERMINATED	Rheumatoid Arthritis	Merck Sharp & Dohme LLC	2007-06	PHASE3
NCT00001965	COMPLETED	Cardiomyopathy, Hypertrophic; Heart Hypertrophy	National Heart, Lung, and Blood Institute (NHLBI)	1999-12	PHASE2
NCT00003920	UNKNOWN	Breast Cancer	University of California, Davis	1996-04	PHASE1
NCT00001212	COMPLETED	Nephrotic Syndrome; Systemic Lupus Erythematosus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	1986-11	PHASE2
NCT00008021	UNKNOWN	Lymphoma	University of California, Davis	2001-02	PHASE1
NCT00002688	UNKNOWN	Leukemia	University Medical Center Groningen	1995-02	PHASE2
NCT00009776	UNKNOWN	Lymphoma	University of California, Davis	2001-03	PHASE1
NCT00001731	COMPLETED	Keratoconjunctivitis Sicca; Sjogren's Syndrome	National Eye Institute (NEI)	1997-11	PHASE2
NCT00458250	COMPLETED	Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute	Tehran University of Medical Sciences	2006-09	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-04-30)

Check the Cyclosporin A product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Cyclosporin A binds to the cytosolic immunophilin cyclophilin, forming a complex that inhibits calcineurin and prevents the dephosphorylation and nuclear translocation of nuclear factor of activated T-cells, thereby suppressing interleukin-2 transcription and T-lymphocyte activation. This targeted immunosuppressive activity suppresses allogeneic immune responses, providing therapeutic utility in organ transplantation such as kidney transplant management and associated complications evaluated in clinical trials.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).